Haemonetics Corp. (HAE): Bathi resik saben saham (EPS TTM)

Stable demand for plasma collection consumables provides Haemonetics Corporation (HAE) with a steady cash flow. Net income per share over the last 12 months (TTM) confirms this trend, with the metric recorded at 2.23. This is supported by a wide range of blood transfusion systems in clinics and the optimization of electronic component supply chains to ensure uninterrupted production.

For an investor in Haemonetics Corporation (HAE), this metric serves as a gauge of profit generation efficiency per share, which is critical for valuing a business in the low-cyclical medical equipment sector. Analyzing the 12-month net income per share trend reveals the result of dividing total annual profit by the number of shares, confirming the high resilience of the company's capital to macroeconomic shocks.